$SOTK

Bagley Stephen James sold $19K of SOTK

Bagley Stephen James (CFO) sold 3,454 shares of SONO TEK CORP (SOTK) at $5.43 on 2026-07-23.

Original reporting
SEC EDGAR · Bagley Stephen James
Published Jul 27, 2026, 8:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SOTK
Neutral
medium confidence
Mentioned
$SOTK
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOTKNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this filing alone does not change the company’s operating outlook.

02

Market read

A newly filed insider sale provides incremental sentiment information, but lacks any fundamental catalyst.

03

What to watch

The article does not state motivations, tax events, or whether other insiders are buying; the post-sale holdings remain sizable (30,800 shares).

Relevance 3/10Novelty 3/10Timing: new Form 4 filed 2026-07-27, covering sale dated 2026-07-23

Background

The article is an SEC Form 4 insider transaction disclosure for Sono Tek Corp, reported by CFO Stephen James Bagley.

Company-level read

Ticker impact

$SOTKNeutralMedium confidence
Context

Sono Tek Corp CFO Bagley sold 3,454 shares in an open-market transaction at $5.4310/share, per a newly filed Form 4.

Expected impact

Likely limited near-term impact; may slightly affect sentiment if traders focus on insider selling.

Evidence & confidence

The filing discloses a specific sale size and price, but provides no new earnings, guidance, deal, or regulatory development.

Market effects

No sector-level read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • SOTK

    Sono Tek Corp, the company whose insider transaction was reported.

  • Stephen James Bagley

    CFO of Sono Tek Corp who reported the open-market sale.

Related articles

$SOTKMedAI 8/10

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Sono-Tek (Nasdaq: SOTK) reported first-quarter fiscal 2027 results for the quarter ended May 31, 2026. Net sales rose 10% to $5.66 million, gross margin expanded to 57% from 52%, operating income increased 86% to $897,000, and net income rose to $741,000 ($0.05 diluted). Cash was $16.65 million with no debt, and backlog was $7.73 million. The company expects continued 1H growth driven by medical demand and higher-value production systems.

$SOTKMed

SONO TEK CORP (SOTK): Results of Operations and Financial Condition

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm SONO-TEK CORPORATION REPORTS FIRST QUARTER FISCAL 2027 RESULTS Exhibit 99.1 Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67% Anticipati

$SOTKMedAI 9/10

Sono-Tek Corporation Q4 2026 Earnings Call Summary

Sono-Tek Corporation reported Q4 2026 results driven by a shift to higher-ASP, turnkey production systems. The company said medical demand rose 54% year over year, while clean energy orders fell 19% amid government policy changes. Gross margin increased to 51% and operating income rose 81%. Management projected growth and profitability in fiscal 2027 H1, with flat-to-modestly higher full-year revenue amid clean-energy uncertainty. Cash was $14.8 million with no debt.

$SOTKMedAI 9/10

Sono-Tek Reports Fiscal Fourth Quarter and Full Year 2026 Financial Results

Sono-Tek (Nasdaq: SOTK) reported FY2026 net sales of $20.9M (+2% YoY), gross margin of 51% (up from 47.5%), operating income of $1.82M (+81%), and net income of about $1.8M (+42%), according to the company. Q4 net sales were $5.6M (+10%). Backlog was $9.1M. The company expects continued 1H FY2027 revenue growth driven by medical and high-ASP systems; FY2027 revenue projected flat to modestly higher.